Table 3.

Exclusion criteria

We exclude patients with any of the following criteria:
1)	Patients with severe heart disease, renal disease, respiratory disease, blood disease, diabetes, coagulopathy, hepatic injury, or renal disorder
2)	Patients with gastric ulcer
3)	Patient with aspirin-induced asthma or history of aspirin
4)	Patients who have had a history of allergic symptoms such as itching and rash, or taking zaltoprofen (Soleton tablet 80 mg, Peon tablet 80 mg, etc.) previously
5)	Hypersensitivity to additives in zaltoprofen (lactose hydrate, corn starch, cellulose, silicic anhydride, hydroxypropyl cellulose, carmellose Ca, stearic acid Mg, polysorbate 80, hypromellose, titanium oxide, talc, carnauba wax) or patient with a history of hypersensitivity
6)	Patients who are administered any of the following agents within 14 days prior to enrollment: tyrosine kinase inhibitors, nonsteroidal anti-inflammatory drugs, thiazolidine derivatives, and drugs with a thiazolysine ring
7)	Patients who have an active range of motion limitation of > 20% with respect to the healthy joint
8)	Patients whose joint space has disappeared by standing position X-ray photography
9)	Patients who are inappropriate for examinations, such as MRI and PETa
10)	Patients who are pregnant or lactating or patients who do not agree to contraception from the final administration of the study drug to 90 days thereafter
11)	Patients who have difficulty taking oral medications
12)	Patients who were using other investigational drugs or using the investigational drug within 3 months prior to the study drug administration
13)	A patient whose investigator or clinical trial doctor judged him/her unsuitable for participation in this trial due to other reasons

^aMRI magnetic resonance imaging, PET positron emission tomography

Please ensure that this wording is correct